Breaking News Instant updates and real-time market news.

AERC

Aeroclean

/

+

10:55
11/24/21
11/24
10:55
11/24/21
10:55

Aeroclean opens at $40, IPO priced at $10 per share

AeroClean Technologies priced 2.5M shares of common stock at a public offering price of $10 per share. Benchmark, HCFP/Capital Markets and Valuable Capital Limited are acting as joint bookrunning managers for the offering. AeroClean is a pathogen elimination technology company that offers continuous air sanitization products under the Purgo brand for hospitals, offices, elevators, aircraft and other shared spaces.

  • 24

    Nov

OTHER BREAKING NEWS FROM THE FLY

Conference/Events
Morgan Stanley consumer/retail analysts hold analyst/industry conference call » 22:15
01/15/22
01/15
22:15
01/15/22
22:15

Restaurants & Food…

Restaurants & Food Distribution Analyst Glass, Dept Store Analyst Greenberger and US Hardlines, Broadlines Analyst Gutman discuss the outlook for the Consumer Industry for 2022 on an Analyst/Industry conference call to be held on January 20 at 11 am.

Conference/Events
Atai Life Sciences to host KOL conference call » 22:15
01/15/22
01/15
22:15
01/15/22
22:15
ATAI

Atai Life Sciences

$5.95 /

-0.26 (-4.19%)

Management holds a Key…

Management holds a Key Opinion Leader conference with Dr. Keefe of Duke University and CEO & Co-Founder Pando of Recognify Life Sciences to discuss the recently completed Phase 2a trial for RL-007 and the preliminary topline data on January 18 at 12 pm. Webcast Link

ShowHide Related Items >><<
ATAI Atai Life Sciences
$5.95 /

-0.26 (-4.19%)

ATAI Atai Life Sciences
$5.95 /

-0.26 (-4.19%)

11/30/21
Fly Intel: Top five analyst initiations
11/30/21 Maxim
Atai Life Sciences initiated with a Buy at Maxim
11/30/21 Maxim
Atai Life Sciences initiated with a Buy at Maxim
11/22/21 Canaccord
Atai Life Sciences weakness a buying opportunity, says Canaccord
ATAI Atai Life Sciences
$5.95 /

-0.26 (-4.19%)

  • 18
    Jun
ATAI Atai Life Sciences
$5.95 /

-0.26 (-4.19%)

ATAI Atai Life Sciences
$5.95 /

-0.26 (-4.19%)

Conference/Events
23andMe to host virtual research and development day » 22:07
01/15/22
01/15
22:07
01/15/22
22:07
ME

23andMe

$5.17 /

-0.25 (-4.62%)

Virtual Research and…

Virtual Research and Development Day to be held on January 18 at 11 am. Webcast Link

ShowHide Related Items >><<
ME 23andMe
$5.17 /

-0.25 (-4.62%)

ME 23andMe
$5.17 /

-0.25 (-4.62%)

11/14/21 Citi
23andMe downgraded to Neutral from Buy at Citi
08/16/21 Credit Suisse
23andMe initiated with an Outperform at Credit Suisse
08/16/21 Citi
23andMe price target lowered to $12 from $14 at Citi
07/13/21 Citi
23andMe initiated with a Buy at Citi
ME 23andMe
$5.17 /

-0.25 (-4.62%)

ME 23andMe
$5.17 /

-0.25 (-4.62%)

ME 23andMe
$5.17 /

-0.25 (-4.62%)

ME 23andMe
$5.17 /

-0.25 (-4.62%)

Conference/Events
Atai Life Sciences to host KOL conference call » 22:04
01/15/22
01/15
22:04
01/15/22
22:04
ATAI

Atai Life Sciences

$5.95 /

-0.26 (-4.19%)

Management holds a Key…

Management holds a Key Opinion Leader conference with Dr. Keefe of Duke University and CEO & Co-Founder Pando of Recognify Life Sciences to discuss the recently completed Phase 2a trial for RL-007 and the preliminary topline data on January 18 at 12 pm. Webcast Link

ShowHide Related Items >><<
ATAI Atai Life Sciences
$5.95 /

-0.26 (-4.19%)

ATAI Atai Life Sciences
$5.95 /

-0.26 (-4.19%)

11/30/21
Fly Intel: Top five analyst initiations
11/30/21 Maxim
Atai Life Sciences initiated with a Buy at Maxim
11/30/21 Maxim
Atai Life Sciences initiated with a Buy at Maxim
11/22/21 Canaccord
Atai Life Sciences weakness a buying opportunity, says Canaccord
ATAI Atai Life Sciences
$5.95 /

-0.26 (-4.19%)

  • 18
    Jun
ATAI Atai Life Sciences
$5.95 /

-0.26 (-4.19%)

ATAI Atai Life Sciences
$5.95 /

-0.26 (-4.19%)

Hot Stocks
GSK says rejected 3 Unilever bids that 'undervalued' Consumer Healthcare unit » 16:37
01/15/22
01/15
16:37
01/15/22
16:37
GSK

GlaxoSmithKline

$45.48 /

+0.44 (+0.98%)

, PFE

Pfizer

$54.94 /

-0.59 (-1.06%)

, UN

Unilever

$60.50 /

+ (+0.00%)

, UL

Unilever

$54.30 /

+0.645 (+1.20%)

A press release was…

A press release was issued today by GlaxoSmithKline (GSK) to the London Stock Exchange, entitled "Update - GSK Consumer Healthcare," that states in part: "GlaxoSmithKline (GSK) plc today confirms that it has received three unsolicited, conditional and non-binding proposals from Unilever plc to acquire the GSK Consumer Healthcare business. The latest proposal received on 20th December 2021 was for a total acquisition value of GBP 50 billion comprising GBP 41.7 billion in cash and GBP 8.3 billion in Unilever shares. The Consumer Healthcare business is a Joint Venture between GSK and Pfizer, with GSK holding a majority controlling interest of 68% and Pfizer 32%. GSK rejected all three proposals made on the basis that they fundamentally undervalued the Consumer Healthcare business and its future prospects. The Board of GSK is strongly focused on maximising value for GSK shareholders and has carefully evaluated each Unilever proposal. In doing so, the Board and its advisers assessed the proposals relative to the financial planning assessments completed to support the proposed demerger of the business in mid-2022, including the sales growth outlook set out below... The business has an exceptional portfolio of world-class, category-leading brands; global scale with footprint and distribution capability to serve more than 100 markets; strong brand building, innovation and digital capabilities; and offers a unique proposition that combines trusted science with human understanding... The business is well-positioned to sustainably grow ahead of its categories in the years to come. The fundamentals for the GBP 150 billion consumer healthcare sector are strong, reflecting an increased focus on health and wellness, significant demand from an ageing population and emerging middle class, and sizeable unmet consumer needs. Over the period 2019-2021 the Consumer Healthcare business delivered a 4% organic sales growth CAGR2 outpacing its categories and despite the adverse impact of the COVID pandemic. Superior sales growth for the business is expected to result from a strategy that puts the consumer at the heart of the business to better address every-day health and wellness needs, in particular by increasing household penetration of its leading brands and capitalising on new and emerging growth opportunities arising from innovation and the use of new technologies and digital platforms, all underpinned by continued strong execution and financial discipline. Over the medium term, superior sales growth is expected to be primarily driven by continued momentum of key brands in Oral Care, VMS, and Pain Relief; accelerating innovation in the US and China; and further growth in emerging markets. Reflecting these trends, and the investments made and planned for the business, the Board of GSK is confident that the Consumer Healthcare business can sustainably deliver annual organic sales growth in the range of 4-6% CER over the medium term. The combination of superior organic sales growth, operating margin expansion and consistent high cash generation will, we believe, offer both existing and prospective shareholders a highly attractive financial profile that facilitates continued investment in growth, the delivery of attractive returns and the opportunity of continued participation in long-term value creation. The Board of GSK unanimously concluded that the proposals were not in the best interests of GSK shareholders as they fundamentally undervalued the Consumer Healthcare business and its future prospects. The Board of GSK therefore remains focused on executing its proposed demerger of the Consumer Healthcare business, to create a new independent global category-leading consumer company which, subject to approval from shareholders, is on track to be achieved in mid-2022. GSK intends to share further details of the strategy, brands, capabilities and operations, including detailed financial information and future growth ambitions for the new Consumer Healthcare business at a virtual Capital Markets Day for investors and analysts on Monday 28th February 2022."

ShowHide Related Items >><<
UN Unilever
$60.50 /

+ (+0.00%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

01/04/22 JPMorgan
GlaxoSmithKline price target raised to 1,710 GBp from 1,580 GBp at JPMorgan
01/04/22 JPMorgan
JPMorgan places 'positive Catalyst watch' on GSK, ups target
12/21/21 H.C. Wainwright
Vir Biotechnology price target raised to $300 from $200 at H.C. Wainwright
12/16/21 Stifel
Adagio story 'even more complicated' after preprints on ADG20, says Stifel
PFE Pfizer
$54.94 /

-0.59 (-1.06%)

01/14/22 BMO Capital
Pfizer price target raised to $76 from $60 at BMO Capital
01/11/22 BofA
Pfizer added to US 1 List; Goldman Sachs removed at BofA
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
UN Unilever
$60.50 /

+ (+0.00%)

01/10/22 Citi
Unilever resumed with a Buy at Citi
11/01/21 Bernstein
Unilever upgraded to Market Perform from Underperform at Bernstein
09/16/21 Deutsche Bank
Unilever downgraded to Hold from Buy at Deutsche Bank
09/02/21 JPMorgan
Unilever downgraded to Underweight from Neutral at JPMorgan
UL Unilever
$54.30 /

+0.645 (+1.20%)

09/02/21
Fly Intel: Top five analyst downgrades
PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

UN Unilever
$60.50 /

+ (+0.00%)

UL Unilever
$54.30 /

+0.645 (+1.20%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

UN Unilever
$60.50 /

+ (+0.00%)

UL Unilever
$54.30 /

+0.645 (+1.20%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

Periodicals
DirecTV to drop One America News in blow to conservative channel, Bloomberg says » 12:38
01/15/22
01/15
12:38
01/15/22
12:38
T

AT&T

$27.18 /

+0.37 (+1.38%)

, TPG

TPG

$32.74 /

-1.24 (-3.65%)

DirecTV, which is owned…

DirecTV, which is owned by AT&T (T) and TPG (TPG) via a joint venture, plans to drop One America News Network, dealing a major blow to the conservative channel that's been criticized for spreading misinformation and had a loyal fan in former President Donald Trump, Bloomberg's Gerry Smith reports. The satellite-TV provider has notified OAN's owner, Herring Networks, that it plans to stop carrying the company's two channels when their contract expires. Herring Networks also owns AWE, a lifestyle channel that stands for "A Wealth of Entertainment." Reference Link

ShowHide Related Items >><<
T AT&T
$27.18 /

+0.37 (+1.38%)

T AT&T
$27.18 /

+0.37 (+1.38%)

01/11/22 Citi
Citi adds Crown Castle, Switch to 'Positive Catalyst Watch List'
01/11/22 Citi
Citi adds AT&T to 'positive catalyst watch list,' keeps $29 target
01/07/22 Wells Fargo
Wells upgrades AT&T to neutral with downside risks 'more limited'
01/07/22 Wells Fargo
AT&T upgraded to Equal Weight from Underweight at Wells Fargo
TPG TPG
$32.74 /

-1.24 (-3.65%)

T AT&T
$27.18 /

+0.37 (+1.38%)

  • 13
    Jan
TPG TPG
$32.74 /

-1.24 (-3.65%)

T AT&T
$27.18 /

+0.37 (+1.38%)

TPG TPG
$32.74 /

-1.24 (-3.65%)

T AT&T
$27.18 /

+0.37 (+1.38%)

T AT&T
$27.18 /

+0.37 (+1.38%)

Periodicals
Barron's sees buying opportunity in Shell buybacks, low-carbon energy shift » 09:48
01/15/22
01/15
09:48
01/15/22
09:48
RDS.A

Royal Dutch Shell

$50.06 /

+0.83 (+1.69%)

, RDS.B

Royal Dutch Shell

$50.09 /

+0.84 (+1.71%)

, COP

ConocoPhillips

$86.80 /

+3.23 (+3.87%)

Activist shareholder…

Activist shareholder Third Point argues that Royal Dutch Shell is worth more if the oil company were broken up, but if the business remains whole, two key factors could enhance its value-the promise to return 20% to 30% of its cash flow from operations to shareholders in dividends and buybacks to 2025, and its shift to low-carbon energy, Rupert Steiner writes in this week's edition of Barron's. This is in addition to Shell 's (RDS.A) plans for $7B of the $9.5B in proceeds from the sale of its Permian basin oil field to ConocoPhillips (COP) to be returned to shareholders, the author notes. Shell's transition to investing in low-carbon solutions is also key to its future growth, the publication adds. Shell's shares, along with many of its peers, have been more than halved since the beginning of the pandemic in January 2020. Now could be a buying opportunity, Steiner contends. Reference Link

ShowHide Related Items >><<
RDS.B Royal Dutch Shell
$50.09 /

+0.84 (+1.71%)

RDS.A Royal Dutch Shell
$50.06 /

+0.83 (+1.69%)

COP ConocoPhillips
$86.80 /

+3.23 (+3.87%)

RDS.A Royal Dutch Shell
$50.06 /

+0.83 (+1.69%)

01/07/22 Exane BNP Paribas
Royal Dutch Shell downgraded to Neutral from Outperform at Exane BNP Paribas
12/03/21 Deutsche Bank
Royal Dutch Shell price target raised to 2,038 GBp at Deutsche Bank
11/17/21 Scotiabank
Royal Dutch Shell upgraded to Outperform at Scotiabank
11/17/21 Scotiabank
Shell Class B upgraded to Outperform from Sector Perform at Scotiabank
RDS.B Royal Dutch Shell
$50.09 /

+0.84 (+1.71%)

11/15/21 UBS
Royal Dutch Shell price target raised to 2,125 GBp from 1,860 GBp at UBS
COP ConocoPhillips
$86.80 /

+3.23 (+3.87%)

01/14/22 Truist
ConocoPhillips price target raised to $111 from $100 at Truist
01/13/22 Scotiabank
ConocoPhillips downgraded to Sector Perform from Outperform at Scotiabank
01/03/22 Mizuho
ConocoPhillips price target lowered to $98 from $101 at Mizuho
11/30/21 Mizuho
ConocoPhillips price target raised to $101 from $99 at Mizuho
RDS.A Royal Dutch Shell
$50.06 /

+0.83 (+1.69%)

COP ConocoPhillips
$86.80 /

+3.23 (+3.87%)

RDS.B Royal Dutch Shell
$50.09 /

+0.84 (+1.71%)

RDS.A Royal Dutch Shell
$50.06 /

+0.83 (+1.69%)

COP ConocoPhillips
$86.80 /

+3.23 (+3.87%)

RDS.B Royal Dutch Shell
$50.09 /

+0.84 (+1.71%)

RDS.A Royal Dutch Shell
$50.06 /

+0.83 (+1.69%)

COP ConocoPhillips
$86.80 /

+3.23 (+3.87%)

COP ConocoPhillips
$86.80 /

+3.23 (+3.87%)

Periodicals
Take-Two playing the long game, stock looks cheap, Barron's says » 09:43
01/15/22
01/15
09:43
01/15/22
09:43
TTWO

Take-Two

$152.57 /

-2.2 (-1.42%)

, ZNGA

Zynga

$8.95 /

-0.1 (-1.10%)

This past week, Take-Two…

This past week, Take-Two (TTWO) made a significant effort to right its ship. The company agreed to buy mobile-game maker Zynga (ZNGA) for $12.7 billion, Connor Smith writes in this week's edition of Barron's. Zynga gives Take-Two a larger roster of game developers along with a treasure trove of data and mobile-advertising resources, the author notes. Most of all, it brings scale, says Take-Two CEO Strauss Zelnick. The stock currently trades at about 23 times earnings estimates for the coming year, below a three-year average of 28 times. At that average multiple, Take-Two shares would be more than 20% higher, at $187. And with Zynga, Take-Two has taken control of its destiny, Smith contends.Reference Link

ShowHide Related Items >><<
ZNGA Zynga
$8.95 /

-0.1 (-1.10%)

TTWO Take-Two
$152.57 /

-2.2 (-1.42%)

TTWO Take-Two
$152.57 /

-2.2 (-1.42%)

01/13/22 Stifel
Zynga downgraded to Hold from Buy at Stifel
01/12/22 BMO Capital
Take-Two upgraded to Outperform from Market Perform at BMO Capital
01/11/22 Truist
Zynga downgraded to Hold from Buy at Truist
01/11/22 KeyBanc
Zynga downgraded to Sector Weight from Overweight at KeyBanc
ZNGA Zynga
$8.95 /

-0.1 (-1.10%)

ZNGA Zynga
$8.95 /

-0.1 (-1.10%)

TTWO Take-Two
$152.57 /

-2.2 (-1.42%)

ZNGA Zynga
$8.95 /

-0.1 (-1.10%)

TTWO Take-Two
$152.57 /

-2.2 (-1.42%)

TTWO Take-Two
$152.57 /

-2.2 (-1.42%)

ZNGA Zynga
$8.95 /

-0.1 (-1.10%)

TTWO Take-Two
$152.57 /

-2.2 (-1.42%)

Periodicals
Data point could signal an Adobe comeback, Barron's says » 09:38
01/15/22
01/15
09:38
01/15/22
09:38
ADBE

Adobe

$520.32 /

+3.95 (+0.76%)

Adobe stock has been…

Adobe stock has been tanking recently-and it's time for it to make a stand. If it can't, long-term investors could be in for a world of hurt, Ben Levisohn writes in this week's edition of Barron's. At $520.60 a share, it is sitting near its 100-week moving average of about $500, which has served as support for the past nine years. And Adobe's relative strength index-a measure of whether a stock is overbought or oversold-fell to 34 early in the week, its most oversold level since 2011, the author notes. Together, they could combine to push the stock higher, the publication adds. Reference Link

ShowHide Related Items >><<
ADBE Adobe
$520.32 /

+3.95 (+0.76%)

ADBE Adobe
$520.32 /

+3.95 (+0.76%)

01/10/22 Piper Sandler
Adobe price target lowered to $600 from $630 at Piper Sandler
01/04/22 UBS
Adobe downgraded to Neutral at UBS on spending pull-forward concerns
01/04/22 UBS
Adobe downgraded to Neutral from Buy at UBS
12/20/21 Citi
Adobe price target lowered to $611 from $678 at Citi
ADBE Adobe
$520.32 /

+3.95 (+0.76%)

ADBE Adobe
$520.32 /

+3.95 (+0.76%)

ADBE Adobe
$520.32 /

+3.95 (+0.76%)

ADBE Adobe
$520.32 /

+3.95 (+0.76%)

Periodicals
Freeport McMoRan could be big winner as miner off to strong start, Barron's says » 09:31
01/15/22
01/15
09:31
01/15/22
09:31
FCX

Freeport McMoRan

$44.08 /

-0.26 (-0.59%)

Concerns about inflation,…

Concerns about inflation, which hit a nearly 40-year high in December, and tighter monetary policy have pushed investors out of growth stocks and into value, and mining stocks have been among the beneficiaries, Ben Levisohn writes in this week's edition of Barron's. Higher copper prices should also help miners when they start reporting earnings this month. Consider Freeport McMoRan, which reports on Jan. 26, the author says. Freeport, at $44.08 a share, could be a big winner. While it is likely to beat earnings and Ebitda estimates, it trades at just 9.8 times 12-month forward earnings, well below its five-year average of 14.4 times, the publication points out. But more than that, it has gone from being cash-strapped to having a solid balance sheet, the author adds. Reference Link

ShowHide Related Items >><<
FCX Freeport McMoRan
$44.08 /

-0.26 (-0.59%)

FCX Freeport McMoRan
$44.08 /

-0.26 (-0.59%)

12/13/21 Stifel
Freeport McMoRan initiated with a Buy at Stifel
11/16/21 Wolfe Research
Freeport McMoRan initiated with an Outperform at Wolfe Research
10/22/21
Fly Intel: Top five analyst downgrades
10/22/21 Argus
Freeport McMoRan price target raised to $45 from $40 at Argus
FCX Freeport McMoRan
$44.08 /

-0.26 (-0.59%)

FCX Freeport McMoRan
$44.08 /

-0.26 (-0.59%)

FCX Freeport McMoRan
$44.08 /

-0.26 (-0.59%)

FCX Freeport McMoRan
$44.08 /

-0.26 (-0.59%)

Periodicals
Angi could be the next Uber, stock looks cheap, Barron's says » 09:27
01/15/22
01/15
09:27
01/15/22
09:27
ANGI

Angi Inc.

$8.20 /

+0.29 (+3.67%)

, ETSY

Etsy

$163.80 /

-2.75 (-1.65%)

, UBER

Uber

$41.53 /

-1.305 (-3.05%)

Revenue for Angi's…

Revenue for Angi's (ANGI) ads and leads business, which is about three-quarters of company revenue, was flat in the latest quarter, even as demand for contractors surged, Nicholas Jasinski writes in this week's edition of Barron's. The company's stock is down 33% over the past 12 months. But Angi is working on a fix and-in a world of pricey internet stocks-the stock now looks like a bargain, the author contends. So far, investors aren't paying attention, with Angi stock trading for just 1.8 times the $2.29 billion in revenue that Wall Street expects the company to generate in 2023, the publication points out. That compares with Angi's five-year average of more than five times year-ahead revenue. Leading online marketplaces like Airbnb (ABNB), Etsy (ETSY), and Uber Technologies (UBER) fetch an average multiple of 6.1, Jasinski adds. Reference Link

ShowHide Related Items >><<
UBER Uber
$41.53 /

-1.305 (-3.05%)

ETSY Etsy
$163.80 /

-2.75 (-1.65%)

ANGI Angi Inc.
$8.20 /

+0.29 (+3.67%)

ANGI Angi Inc.
$8.20 /

+0.29 (+3.67%)

01/06/22 Goldman Sachs
Angi Inc. assumed with a Buy at Goldman Sachs
12/15/21 JPMorgan
Angi Inc. price target lowered to $13 from $17 at JPMorgan
11/08/21 Piper Sandler
IAC price target raised to $168 from $158 at Piper Sandler
11/08/21 Piper Sandler
Angi Inc. price target lowered to $12 from $13 at Piper Sandler
ETSY Etsy
$163.80 /

-2.75 (-1.65%)

01/12/22 Stifel
Etsy price target lowered to $230 from $265 at Stifel
12/02/21 UBS
Etsy initiated with a Sell at UBS
11/24/21 Wedbush
Etsy price target raised to $310 from $264 at Wedbush
11/24/21 Citi
Etsy price target raised to $320 from $245 at Citi
UBER Uber
$41.53 /

-1.305 (-3.05%)

01/13/22 Mizuho
Regulatory trends favorable for gig economy companies, says Mizuho
01/11/22 JPMorgan
Amazon 'strong favorite' to be best performing FANG stock, JPMorgan says
01/07/22 Needham
Needham names Uber Top Pick for 2022, lowers price target to $75 from $77
01/07/22 Jefferies
Jefferies sees Lyft trailing Uber in 2022, downgrades to Hold
UBER Uber
$41.53 /

-1.305 (-3.05%)

ETSY Etsy
$163.80 /

-2.75 (-1.65%)

ANGI Angi Inc.
$8.20 /

+0.29 (+3.67%)

  • 29
    Jul
UBER Uber
$41.53 /

-1.305 (-3.05%)

ETSY Etsy
$163.80 /

-2.75 (-1.65%)

UBER Uber
$41.53 /

-1.305 (-3.05%)

ETSY Etsy
$163.80 /

-2.75 (-1.65%)

ANGI Angi Inc.
$8.20 /

+0.29 (+3.67%)

UBER Uber
$41.53 /

-1.305 (-3.05%)

ETSY Etsy
$163.80 /

-2.75 (-1.65%)

On The Fly
Opening Day: TPG raises $1B in first big IPO of 2022 » 09:15
01/15/22
01/15
09:15
01/15/22
09:15
TPG

TPG

$32.74 /

-1.24 (-3.65%)

, CFSB

CFSB Bancorp

$10.49 /

+0.28 (+2.74%)

, HILS

Hillstream BioPharma

$2.89 /

+0.1 (+3.58%)

, PEV

Phoenix Motor

/

+

, NUVO

Nuvo Group

/

+

, AUST

Austin Gold

/

+

, CHO

Chobani

/

+

, CAST

FreeCast

/

+

, SPI

SPI Energy

$3.41 /

+ (+0.00%)

, F

Ford

$25.19 /

+0.18 (+0.72%)

, UBER

Uber

$41.53 /

-1.305 (-3.05%)

, SPOT

Spotify

$218.50 /

-7.75 (-3.43%)

TPG raised $1B in its…

ShowHide Related Items >><<
UBER Uber
$41.53 /

-1.305 (-3.05%)

SPOT Spotify
$218.50 /

-7.75 (-3.43%)

SPI SPI Energy
$3.41 /

+ (+0.00%)

F Ford
$25.19 /

+0.18 (+0.72%)

TPG TPG
$32.74 /

-1.24 (-3.65%)

CFSB CFSB Bancorp
$10.49 /

+0.28 (+2.74%)

HILS Hillstream BioPharma
$2.89 /

+0.1 (+3.58%)

PEV Phoenix Motor
/

+

NUVO Nuvo Group
/

+

AUST Austin Gold
/

+

CHO Chobani
/

+

CAST FreeCast
/

+

SPI SPI Energy
$3.41 /

+ (+0.00%)

09/27/21 Maxim
Maxim starts SPI Energy at Buy on contribution from EV initiatives
09/27/21 Maxim
SPI Energy initiated with a Buy at Maxim
F Ford
$25.19 /

+0.18 (+0.72%)

01/14/22 RBC Capital
Ford downgraded to Sector Perform at RBC Capital on reduced near-term upside
01/14/22 RBC Capital
Ford downgraded to Sector Perform from Outperform at RBC Capital
01/13/22 Deutsche Bank
Deutsche Bank sees 2022 guidance misses from these auto companies
01/13/22 Deutsche Bank
Ford price target raised to $24 from $18 at Deutsche Bank
UBER Uber
$41.53 /

-1.305 (-3.05%)

01/13/22 Mizuho
Regulatory trends favorable for gig economy companies, says Mizuho
01/11/22 JPMorgan
Amazon 'strong favorite' to be best performing FANG stock, JPMorgan says
01/07/22 Needham
Needham names Uber Top Pick for 2022, lowers price target to $75 from $77
01/07/22 Jefferies
Jefferies sees Lyft trailing Uber in 2022, downgrades to Hold
SPOT Spotify
$218.50 /

-7.75 (-3.43%)

12/28/21 Evercore ISI
Evercore ISI's Mark Mahaney announces top internet picks for 2022
11/24/21
Fly Intel: Top five analyst initiations
11/24/21 Benchmark
Spotify initiated with a Buy at Benchmark
11/17/21 Goldman Sachs
Amazon named top Americas Internet pick for 2022 at Goldman Sachs
UBER Uber
$41.53 /

-1.305 (-3.05%)

SPOT Spotify
$218.50 /

-7.75 (-3.43%)

F Ford
$25.19 /

+0.18 (+0.72%)

  • 12
    Jan
  • 13
    Jan
  • 24
    Nov
  • 29
    Jul
UBER Uber
$41.53 /

-1.305 (-3.05%)

TPG TPG
$32.74 /

-1.24 (-3.65%)

SPOT Spotify
$218.50 /

-7.75 (-3.43%)

F Ford
$25.19 /

+0.18 (+0.72%)

UBER Uber
$41.53 /

-1.305 (-3.05%)

SPOT Spotify
$218.50 /

-7.75 (-3.43%)

PEV Phoenix Motor
/

+

F Ford
$25.19 /

+0.18 (+0.72%)

UBER Uber
$41.53 /

-1.305 (-3.05%)

SPOT Spotify
$218.50 /

-7.75 (-3.43%)

SPI SPI Energy
$3.41 /

+ (+0.00%)

F Ford
$25.19 /

+0.18 (+0.72%)

Hot Stocks
Unilever confirms approach made to GSK, Pfizer about GSK Consumer Healthcare » 07:42
01/15/22
01/15
07:42
01/15/22
07:42
UN

Unilever

$60.50 /

+ (+0.00%)

, UL

Unilever

$54.30 /

+0.645 (+1.20%)

, GSK

GlaxoSmithKline

$45.48 /

+0.44 (+0.98%)

, PFE

Pfizer

$54.94 /

-0.59 (-1.06%)

Unilever (UN, UL) has…

Unilever (UN, UL) has issued the following statement in response to press reporting: "Unilever notes recent reporting regarding its interest in GSK Consumer Healthcare and confirms that it has approached GSK and Pfizer about a potential acquisition of the business. GSK Consumer Healthcare is a leader in the attractive consumer health space and would be a strong strategic fit as Unilever continues to re-shape its portfolio. There can be no certainty that any agreement will be reached."

ShowHide Related Items >><<
UN Unilever
$60.50 /

+ (+0.00%)

UL Unilever
$54.30 /

+0.645 (+1.20%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

UN Unilever
$60.50 /

+ (+0.00%)

01/10/22 Citi
Unilever resumed with a Buy at Citi
11/01/21 Bernstein
Unilever upgraded to Market Perform from Underperform at Bernstein
09/16/21 Deutsche Bank
Unilever downgraded to Hold from Buy at Deutsche Bank
09/02/21 JPMorgan
Unilever downgraded to Underweight from Neutral at JPMorgan
UL Unilever
$54.30 /

+0.645 (+1.20%)

09/02/21
Fly Intel: Top five analyst downgrades
GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

01/04/22 JPMorgan
GlaxoSmithKline price target raised to 1,710 GBp from 1,580 GBp at JPMorgan
01/04/22 JPMorgan
JPMorgan places 'positive Catalyst watch' on GSK, ups target
12/21/21 H.C. Wainwright
Vir Biotechnology price target raised to $300 from $200 at H.C. Wainwright
12/16/21 Stifel
Adagio story 'even more complicated' after preprints on ADG20, says Stifel
PFE Pfizer
$54.94 /

-0.59 (-1.06%)

01/14/22 BMO Capital
Pfizer price target raised to $76 from $60 at BMO Capital
01/11/22 BofA
Pfizer added to US 1 List; Goldman Sachs removed at BofA
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

UN Unilever
$60.50 /

+ (+0.00%)

UL Unilever
$54.30 /

+0.645 (+1.20%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

UN Unilever
$60.50 /

+ (+0.00%)

UL Unilever
$54.30 /

+0.645 (+1.20%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

Periodicals
GSK rejected unsolicited GBP 50B bid from Unilever for consumer unit, Times says » 07:40
01/15/22
01/15
07:40
01/15/22
07:40
UN

Unilever

$60.50 /

+ (+0.00%)

, UL

Unilever

$54.30 /

+0.645 (+1.20%)

, GSK

GlaxoSmithKline

$45.48 /

+0.44 (+0.98%)

, PFE

Pfizer

$54.94 /

-0.59 (-1.06%)

Unilever (UN, UL) made an…

Unilever (UN, UL) made an unsolicited bid for GlaxoSmithKline's (GSK) consumer goods business worth roughly GBP 50B, which was rejected on the basis that it was too cheap, The Sunday Times' Oliver Shah and Sabah Meddings reported. Drug making giant Pfizer (PFE), which owns a minority stake in the division, was involved in the decision to decline the offer, the report noted. Reference Link

ShowHide Related Items >><<
UN Unilever
$60.50 /

+ (+0.00%)

UL Unilever
$54.30 /

+0.645 (+1.20%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

UN Unilever
$60.50 /

+ (+0.00%)

01/10/22 Citi
Unilever resumed with a Buy at Citi
11/01/21 Bernstein
Unilever upgraded to Market Perform from Underperform at Bernstein
09/16/21 Deutsche Bank
Unilever downgraded to Hold from Buy at Deutsche Bank
09/02/21 JPMorgan
Unilever downgraded to Underweight from Neutral at JPMorgan
UL Unilever
$54.30 /

+0.645 (+1.20%)

09/02/21
Fly Intel: Top five analyst downgrades
GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

01/04/22 JPMorgan
GlaxoSmithKline price target raised to 1,710 GBp from 1,580 GBp at JPMorgan
01/04/22 JPMorgan
JPMorgan places 'positive Catalyst watch' on GSK, ups target
12/21/21 H.C. Wainwright
Vir Biotechnology price target raised to $300 from $200 at H.C. Wainwright
12/16/21 Stifel
Adagio story 'even more complicated' after preprints on ADG20, says Stifel
PFE Pfizer
$54.94 /

-0.59 (-1.06%)

01/14/22 BMO Capital
Pfizer price target raised to $76 from $60 at BMO Capital
01/11/22 BofA
Pfizer added to US 1 List; Goldman Sachs removed at BofA
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

UN Unilever
$60.50 /

+ (+0.00%)

UL Unilever
$54.30 /

+0.645 (+1.20%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

UN Unilever
$60.50 /

+ (+0.00%)

UL Unilever
$54.30 /

+0.645 (+1.20%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

General news
Treasury Market Summary » 22:15
01/14/22
01/14
22:15
01/14/22
22:15
$ECON

Economic Data

/

+

Treasury Market Summary:…

Treasury Market Summary: it was another meltdown in the markets as worries over rising inflation, fears over Fed tightening and a potential mistake, concerns over a significant slowing in growth, and jitters over the negative impacts on earnings of surging wages and expenses knocked bonds and stocks sharply lower to end the week. With the bears in firm control, buyers remained mostly sidelined and unwilling to backstop the erosion in Treasuries. Rates jumped with the front end rising over 7 bps with the 2-year hitting 0.968% and the 10-year surging 8 bps to 1.784%. However, Wall Street managed to recover from another round of steep declines. The S&P 500 recovered from a -1% drop to finish with a 0.08% gain. The NASDAQ rallied 0.59%, erasing a -0.7% slide. The Dow close with a -0.56% loss, though the index had posted as much as a -1.3% decline earlier.

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

Periodicals
DirecTV to drop One America News, Bloomberg says  18:49
01/14/22
01/14
18:49
01/14/22
18:49
T

AT&T

$27.18 /

+0.37 (+1.38%)

, TPG

TPG

$32.74 /

-1.24 (-3.65%)

 
ShowHide Related Items >><<
T AT&T
$27.18 /

+0.37 (+1.38%)

T AT&T
$27.18 /

+0.37 (+1.38%)

01/11/22 Citi
Citi adds Crown Castle, Switch to 'Positive Catalyst Watch List'
01/11/22 Citi
Citi adds AT&T to 'positive catalyst watch list,' keeps $29 target
01/07/22 Wells Fargo
Wells upgrades AT&T to neutral with downside risks 'more limited'
01/07/22 Wells Fargo
AT&T upgraded to Equal Weight from Underweight at Wells Fargo
TPG TPG
$32.74 /

-1.24 (-3.65%)

T AT&T
$27.18 /

+0.37 (+1.38%)

  • 13
    Jan
TPG TPG
$32.74 /

-1.24 (-3.65%)

T AT&T
$27.18 /

+0.37 (+1.38%)

T AT&T
$27.18 /

+0.37 (+1.38%)

T AT&T
$27.18 /

+0.37 (+1.38%)

Hot Stocks
NineDot Energy announces investment from funds managed by Carlyle Group » 18:24
01/14/22
01/14
18:24
01/14/22
18:24
CG

Carlyle Group

$51.20 /

-0.62 (-1.20%)

NineDot Energy announced…

NineDot Energy announced a strategic investment from funds managed by Carlyle. Carlyle's investment will enable NineDot to develop, build, and operate over 400 megawatts of clean energy systems by 2026 that strengthen local power grid infrastructure and provide stable, reliable, and resilient power to tens of thousands of New York households and businesses. Founded in 2015, NineDot Energy is a New York City-based clean-tech developer that designs and deploys community-scale energy generation and battery storage projects. Carlyle's investment is intended to enable NineDot to execute on its pipeline of battery storage projects in Downstate New York including Queens, Staten Island, the Bronx, and Long Island. These projects support New York State's mission to achieve its goal of 100% clean energy by 2040, including a recently doubled target of 6,000 MW of energy storage by 2030.

ShowHide Related Items >><<
CG Carlyle Group
$51.20 /

-0.62 (-1.20%)

CG Carlyle Group
$51.20 /

-0.62 (-1.20%)

12/17/21 Deutsche Bank
Carlyle Group price target raised to $72 from $70 at Deutsche Bank
12/16/21 BofA
Carlyle Group initiated with a Buy at BofA
12/16/21 BofA
Carlyle Group initiated with a Buy at BofA
11/02/21 Citi
Carlyle Group price target raised to $73 from $66 at Citi
CG Carlyle Group
$51.20 /

-0.62 (-1.20%)

  • 10
    Nov
  • 19
    May
  • 12
    Mar
CG Carlyle Group
$51.20 /

-0.62 (-1.20%)

CG Carlyle Group
$51.20 /

-0.62 (-1.20%)

Hot Stocks
Academy Sports CEO Hicks buys 20,000 common shares » 18:18
01/14/22
01/14
18:18
01/14/22
18:18
ASO

Academy Sports

$38.41 /

-1.6201 (-4.05%)

In a regulatory filing,…

In a regulatory filing, Academy Sports & Outdoors chairman, president, and CEO Ken Hicks disclosed the purchase of 20,000 common shares of the company on January 14 at a price of $38.91 per share.

ShowHide Related Items >><<
ASO Academy Sports
$38.41 /

-1.6201 (-4.05%)

ASO Academy Sports
$38.41 /

-1.6201 (-4.05%)

12/14/21
Fly Intel: Top five analyst upgrades
12/14/21 Goldman Sachs
Academy Sports upgraded to Buy from Neutral at Goldman Sachs
12/06/21 UBS
Academy Sports price target raised to $56 from $52 at UBS
10/25/21 Wedbush
Academy Sports initiated with an Outperform at Wedbush
ASO Academy Sports
$38.41 /

-1.6201 (-4.05%)

  • 15
    Sep
  • 06
    May
  • 08
    Apr
  • 28
    Jan
ASO Academy Sports
$38.41 /

-1.6201 (-4.05%)

ASO Academy Sports
$38.41 /

-1.6201 (-4.05%)

ASO Academy Sports
$38.41 /

-1.6201 (-4.05%)

Earnings
Ion Geophysical reports preliminary Q4 revenue $40M, consensus $33.73M » 17:59
01/14/22
01/14
17:59
01/14/22
17:59
IO

Ion Geophysical

/

+

ION announced that the…

ION announced that the company expects fourth quarter 2021 revenues to be approximately $40M, an increase of 45% year-over-year. While expected fourth quarter 2021 revenues declined by 10% sequentially, second half fiscal year revenues delivered an increase of approximately 150% over the first half year's revenues. "Fourth quarter revenues improved year-over-year, consistent with our expectations of momentum building from our growing data library and maritime digitalization strategy," said Chris Usher, ION's President and Chief Executive Officer. "Sales of the latest phases of our Brazil 3D reprocessing program, Picanha, illustrate the value clients ascribe to this program which now tops over 150,000 contiguous square kilometers in the Campos and Santos basins. The third and fully underwritten extension of our new 3D program in the North Sea has concluded acquisition for the season. Our traditional BasinSPAN 2D programs continue to demonstrate resilience through sales in Africa and Brazil, despite the pullback in exploration spending. And lastly, our software business continues to expand into new markets. On December 17, 2021, we announced awards for MarlinTM in the areas of simultaneous operations and country-scale port management. Our latest contract is for a five-year deployment of Marlin to optimize offshore logistics in the Asia Pacific region for a supermajor."

ShowHide Related Items >><<
IO Ion Geophysical
/

+

IO Ion Geophysical
/

+

08/16/21 Alliance Global Partners
Ion Geophysical price target lowered to $3.70 from $4.20 at Alliance Global
06/02/21 Alliance Global Partners
Ion Geophysical initiated with a Buy at Alliance Global Partners
02/16/21 H.C. Wainwright
Ion Geophysical price target raised to $10 from $4 at H.C. Wainwright
IO Ion Geophysical
/

+

IO Ion Geophysical
/

+

Syndicate
China SXT Pharmaceuticals announces offering of ordinary shares, warrants » 17:45
01/14/22
01/14
17:45
01/14/22
17:45
SXTC

China SXT Pharmaceuticals

/

+

China SXT Pharmaceuticals…

China SXT Pharmaceuticals announced that it intends to offer in an underwritten public offering its ordinary shares and prefunded warrants to purchase ordinary shares. The pre-funded warrants shall be offered at the same price per share as the ordinary shares, less the $0.0001 per share exercise price of each pre-funded warrant. The company intends to use the net proceeds from this offering for general corporate purposes, including, but not limited to, working capital and other business opportunities. The base offering is expected to be up to approximately $3.4M, and the underwriter will receive an overallotment option to purchase an additional 15% of the number of ordinary shares and/or pre-funded warrants sold for 45 days following the closing. Aegis Capital Corp. is acting as the sole book-running manager for the offering

ShowHide Related Items >><<
SXTC China SXT Pharmaceuticals
/

+

Periodicals
Houghton Mifflin exploring sale, Bloomberg reports » 17:42
01/14/22
01/14
17:42
01/14/22
17:42
HMHC

Houghton Mifflin

$15.95 /

+0.49 (+3.17%)

Houghton Mifflin is…

Houghton Mifflin is considering a potential sale, Bloomberg's Kiel Porter and Liana Baker report, citing people familiar with the matter. The company is working with an adviser, said the people, who asked not to be identified because they weren't authorized to speak publicly. Private equity firms are weighing bids for the company, the people said. No final decision has been made and the company could opt to remain independent, they added. Reference Link

ShowHide Related Items >><<
HMHC Houghton Mifflin
$15.95 /

+0.49 (+3.17%)

HMHC Houghton Mifflin
$15.95 /

+0.49 (+3.17%)

01/11/22 BMO Capital
Houghton Mifflin upgraded to Outperform from Market Perform at BMO Capital
11/08/21 BMO Capital
Houghton Mifflin price target raised to $19 from $15 at BMO Capital
03/03/21 BMO Capital
Houghton Mifflin price target raised to $6 from $3 at BMO Capital
HMHC Houghton Mifflin
$15.95 /

+0.49 (+3.17%)

HMHC Houghton Mifflin
$15.95 /

+0.49 (+3.17%)

Syndicate
Ra Medical Systems files $15M mixed securities shelf » 17:34
01/14/22
01/14
17:34
01/14/22
17:34
RMED

Ra Medical Systems

$1.38 /

-0.04 (-2.82%)

Ladenburg Thalmann &…

Ladenburg Thalmann & Co. is acting as sole book-running manager.

ShowHide Related Items >><<
RMED Ra Medical Systems
$1.38 /

-0.04 (-2.82%)

RMED Ra Medical Systems
$1.38 /

-0.04 (-2.82%)

10/21/21 H.C. Wainwright
Ra Medical Systems initiated with a Buy at H.C. Wainwright
03/17/21 Maxim
Ra Medical Systems downgraded to Hold from Buy at Maxim
03/17/21 Maxim
Ra Medical Systems downgraded to Hold from Buy at Maxim
01/27/21 Piper Sandler
Ra Medical making progress on catheter durability, says Piper Sandler
Hot Stocks
Camber Energy receives communication from NYSE American » 17:33
01/14/22
01/14
17:33
01/14/22
17:33
CEI

Camber Energy

/

+

Camber Energy, Inc.…

Camber Energy, Inc. announced that on January 14, 2022 it received a letter from the NYSE American in response to the Company's request for an extension of the date by which the Company is to file outstanding financial reports. The Company is not in compliance with the Exchange's continued listing standards as set forth in Section 1007 of the NYSE American Company Guide(the "Company Guide") given the Company failed to timely file (the "Filing Delinquency") the following reports (collectively, the "Delayed Reports"): (i) Form 10-K for the 9-month transition period ended December 31, 2020; (ii) Form 10-Q for the period ended March 31, 2021; (iii) Form 10-Q for the period ended June 30, 2021; and (iv) Form 10-Q for the period ended September 30, 2021. The Filing Delinquency will be cured via the filing of the Delayed Reports. The Company intended to remedy the Filing Delinquency on or before January 14, 2022, however due to certain circumstances requested the Exchange grant the Company a brief extension of time by which to file the Delayed Reports. The Exchange accepted the Company's request and has allowed the Company until February 15, 2022 to file the Delayed Reports.

ShowHide Related Items >><<
CEI Camber Energy
/

+

CEI Camber Energy
/

+

CEI Camber Energy
/

+

CEI Camber Energy
/

+

Hot Stocks
Armstrong Flooring announces increases in U.S. prices, effective March 1 » 17:32
01/14/22
01/14
17:32
01/14/22
17:32
AFI

Armstrong Flooring

$2.28 /

+0.105 (+4.83%)

Armstrong Flooring…

Armstrong Flooring announced it will increase U.S. prices effective March 1 to offset rising input costs. For select Residential products, price increases will range from 0%-10%. For select Commercial products, price increases will range from 0%-15%. The previously announced and implemented ocean and freight surcharges will remain in place.

ShowHide Related Items >><<
AFI Armstrong Flooring
$2.28 /

+0.105 (+4.83%)

AFI Armstrong Flooring
$2.28 /

+0.105 (+4.83%)

AFI Armstrong Flooring
$2.28 /

+0.105 (+4.83%)

Syndicate
Fathom files to sell 7M shares of Class A common stock for holders  17:21
01/14/22
01/14
17:21
01/14/22
17:21
FATH

Fathom

$7.89 /

+0.97 (+14.02%)

 
ShowHide Related Items >><<
FATH Fathom
$7.89 /

+0.97 (+14.02%)

FATH Fathom
$7.89 /

+0.97 (+14.02%)

FATH Fathom
$7.89 /

+0.97 (+14.02%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.